RESMETIROM
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.7M | 13,832 | 7,511 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.3M | 144 | 75.5% |
| Food and Beverage | $370,657 | 13,659 | 21.9% |
| Honoraria | $43,445 | 24 | 2.6% |
| Travel and Lodging | $1,651 | 5 | 0.1% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | Madrigal Pharmaceuticals | $1.3M | 0 |
Top Doctors Receiving Payments for RESMETIROM — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Gastroenterology | Doylestown, PA | $352.48 | 6 |
| Seania Bristol | Acute Care | Mesa, AZ | $348.10 | 4 |
| , M.D | Hepatology | Baltimore, MD | $344.72 | 7 |
| , MD | Internal Medicine | New York, NY | $344.48 | 5 |
| , MD | Gastroenterology | Brooklyn, NY | $341.63 | 9 |
| , M.D | Internal Medicine | Buffalo, NY | $334.45 | 6 |
| , DO | Internal Medicine | Hartford, CT | $334.23 | 4 |
| , PA-C | Physician Assistant | Pasadena, CA | $333.29 | 10 |
| , M.D | Gastroenterology | New York, NY | $329.27 | 10 |
| , M.D | Gastroenterology | Englewood, CO | $326.79 | 4 |
| , M.D | Gastroenterology | Walnut Creek, CA | $323.01 | 6 |
| , PA-C | Physician Assistant | New Orleans, LA | $317.75 | 4 |
| , M.D | Transplant Hepatology | Los Angeles, CA | $316.74 | 3 |
| , MD | Hospitalist | San Diego, CA | $316.66 | 3 |
| , MD | Hepatology | Newark, NJ | $315.67 | 10 |
| , P.A. -C | Physician Assistant | Atlanta, GA | $311.35 | 6 |
| , MD | Gastroenterology | Cleveland, OH | $310.21 | 9 |
| , M.D | Gastroenterology | Lancaster, CA | $308.11 | 9 |
| , MD | Transplant Hepatology | Washington, DC | $298.28 | 6 |
| , M.D | Transplant Surgery | Macon, GA | $298.14 | 7 |
| , D.O | Internal Medicine | Salt Lake City, UT | $297.50 | 2 |
| , M.D | Gastroenterology | Dallas, TX | $297.49 | 2 |
| , MD | Gastroenterology | San Diego, CA | $295.51 | 4 |
| , MD | Gastroenterology | New Brunswick, NJ | $294.56 | 3 |
| , CRNP | Family | Annapolis, MD | $292.93 | 3 |
Manufacturing Companies
- Madrigal Pharmaceuticals $1.7M
Product Information
- Type Drug
- Total Payments $1.7M
- Total Doctors 7,511
- Transactions 13,832
About RESMETIROM
RESMETIROM is a drug associated with $1.7M in payments to 7,511 healthcare providers, recorded across 13,832 transactions in the CMS Open Payments database. The primary manufacturer is Madrigal Pharmaceuticals.
Payment data is available from 2024 to 2024. In 2024, $1.7M was paid across 13,832 transactions to 7,511 doctors.
The most common payment nature for RESMETIROM is "Unspecified" ($1.3M, 75.5% of total).
RESMETIROM is associated with 1 research study, including "A 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)" ($1.3M).